332 related articles for article (PubMed ID: 18762220)
21. Early Protection against Pertussis Induced by Live Attenuated
Debrie AS; Mielcarek N; Lecher S; Roux X; Sirard JC; Locht C
J Immunol; 2019 Dec; 203(12):3293-3300. PubMed ID: 31732529
[TBL] [Abstract][Full Text] [Related]
22. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
Mielcarek N; Debrie AS; Raze D; Quatannens J; Engle J; Goldman WE; Locht C
Vaccine; 2006 Apr; 24 Suppl 2():S2-54-5. PubMed ID: 16823926
[TBL] [Abstract][Full Text] [Related]
23. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
Komatsu E; Yamaguchi F; Eguchi M; Watanabe M
Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876
[TBL] [Abstract][Full Text] [Related]
24. Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella pertussis Disease and Infection.
Locht C; Papin JF; Lecher S; Debrie AS; Thalen M; Solovay K; Rubin K; Mielcarek N
J Infect Dis; 2017 Jul; 216(1):117-124. PubMed ID: 28535276
[TBL] [Abstract][Full Text] [Related]
25. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.
Skerry CM; Mahon BP
Clin Vaccine Immunol; 2011 Feb; 18(2):187-93. PubMed ID: 21147936
[TBL] [Abstract][Full Text] [Related]
26. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis.
Feunou PF; Bertout J; Locht C
PLoS One; 2010 Apr; 5(4):e10178. PubMed ID: 20419113
[TBL] [Abstract][Full Text] [Related]
27. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.
Skerry CM; Cassidy JP; English K; Feunou-Feunou P; Locht C; Mahon BP
Clin Vaccine Immunol; 2009 Sep; 16(9):1344-51. PubMed ID: 19625486
[TBL] [Abstract][Full Text] [Related]
28. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e.
Li R; Lim A; Ow ST; Phoon MC; Locht C; Chow VT; Alonso S
Vaccine; 2011 Jul; 29(33):5502-11. PubMed ID: 21624415
[TBL] [Abstract][Full Text] [Related]
29. Comparison of real-time PCR and pyrosequencing for typing Bordetella pertussis toxin subunit 1 variants.
Storm M; Advani A; Pettersson M; Hallander HO; Bondeson K
J Microbiol Methods; 2006 Apr; 65(1):153-8. PubMed ID: 16095736
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.
Jahnmatz M; Richert L; Al-Tawil N; Storsaeter J; Colin C; Bauduin C; Thalen M; Solovay K; Rubin K; Mielcarek N; Thorstensson R; Locht C;
Lancet Infect Dis; 2020 Nov; 20(11):1290-1301. PubMed ID: 32687804
[TBL] [Abstract][Full Text] [Related]
31. IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine.
Solans L; Debrie AS; Borkner L; Aguiló N; Thiriard A; Coutte L; Uranga S; Trottein F; Martín C; Mills KHG; Locht C
Mucosal Immunol; 2018 Nov; 11(6):1753-1762. PubMed ID: 30115992
[TBL] [Abstract][Full Text] [Related]
32. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
[TBL] [Abstract][Full Text] [Related]
33. Insight into evolution of Bordetella pertussis from comparative genomic analysis: evidence of vaccine-driven selection.
Octavia S; Maharjan RP; Sintchenko V; Stevenson G; Reeves PR; Gilbert GL; Lan R
Mol Biol Evol; 2011 Jan; 28(1):707-15. PubMed ID: 20833694
[TBL] [Abstract][Full Text] [Related]
34. [Engineering of attenuated Bordetella pertussis bacteria producing immunogenic non-toxic form of pertussis toxin].
Siniashina LN; Nechaeva EV; Amelina IP; Karataev GI
Zh Mikrobiol Epidemiol Immunobiol; 2009; (6):89-94. PubMed ID: 20095432
[TBL] [Abstract][Full Text] [Related]
35. Rapid and accurate typing of Bordetella pertussis targeting genes encoding acellular vaccine antigens using real time PCR and High Resolution Melt analysis.
Chan WF; Maharjan RP; Reeves PR; Sintchenko V; Gilbert GL; Lan R
J Microbiol Methods; 2009 Jun; 77(3):326-9. PubMed ID: 19341769
[TBL] [Abstract][Full Text] [Related]
36. Investigating pertussis toxin and its impact on vaccination.
Coutte L; Locht C
Future Microbiol; 2015; 10(2):241-54. PubMed ID: 25689536
[TBL] [Abstract][Full Text] [Related]
37. Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.
Kamachi K; Arakawa Y
Vaccine; 2007 Jan; 25(6):1000-6. PubMed ID: 17050047
[TBL] [Abstract][Full Text] [Related]
38. Bordetella pertussis from functional genomics to intranasal vaccination.
Locht C; Antoine R; Raze D; Mielcarek N; Hot D; Lemoine Y; Mascart F
Int J Med Microbiol; 2004 Apr; 293(7-8):583-8. PubMed ID: 15149035
[TBL] [Abstract][Full Text] [Related]
39. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates.
Ho SY; Chua SQ; Foo DG; Locht C; Chow VT; Poh CL; Alonso S
Infect Immun; 2008 Jan; 76(1):111-9. PubMed ID: 17954727
[TBL] [Abstract][Full Text] [Related]
40. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.
Denoël P; Godfroid F; Guiso N; Hallander H; Poolman J
Vaccine; 2005 Nov; 23(46-47):5333-41. PubMed ID: 16054273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]